Depth · Rigour · Sensitivity
The “why” behind the data, at global scale
Numbers tell you what is happening in a rare disease population. By contrast, qualitative research tells you why — and in rare disease drug development, the why is frequently the deciding variable. Why do patients delay diagnosis for years? Why do physicians reach for an off-label option when a licensed therapy exists? Why does a support programme with strong enrolment produce poor adherence?
Accordingly, MedPanel’s rare disease qualitative research programmes answer those questions with the methodological rigour, emotional sensitivity, and specialist knowledge that rare and ultra-rare conditions demand. For teams in medical affairs, patient advocacy, HEOR, and commercial, qualitative evidence is not supplementary to the data story — it is often the foundation of it.
In-depth interviews
Built into every protocol
Secure remote, multi-language
Themes · Journeys · Verbatim · Manuscript
IDIs vs Focus Groups for Rare Disease Populations
The most consequential methodological decision in any rare disease qualitative research programme is whether to use in-depth interviews or focus groups. Notably, in rare disease the answer is rarely the same as it would be in a common disease setting.
In-depth interviews (IDIs)
IDIs are the dominant format in rare disease qualitative research, for reasons rooted in both population structure and subject matter. Specifically, rare disease patients often carry complex, emotionally charged histories — diagnostic odysseys spanning years, treatments that failed, and a condition identity that is frequently isolating. Therefore, IDIs create the one-to-one environment in which that depth of experience can be surfaced without the social moderation effects that group settings introduce. For sensitive symptom disclosure, treatment decision-making, caregiver burden, psychological impact, or end-of-life considerations, IDIs are almost always the appropriate format.
Moreover, IDIs are structurally better suited to rare disease’s epidemiological realities. For example, when a condition affects fewer than ten thousand people globally, assembling a group of patients with similar disease profiles in the same time zone and at the same level of progression is operationally prohibitive. As a result, IDIs enable sequential recruitment across geographies and time zones without sacrificing sample coherence.
Focus groups
Focus groups have a defined and valuable role in rare disease qualitative research, but that role is specific. In particular, they perform best when the objective is concept evaluation rather than experience elicitation — testing label comprehension language, assessing patient support programme collateral, evaluating disease awareness messaging, or generating consensus on PRO instrument content. In these applications, the group dynamic is a feature: participants build on each other’s responses, surface language preferences collaboratively, and signal reactions to stimuli in ways sequential interviews cannot replicate.
However, the important caveat is participant selection. Specifically, rare disease focus groups must be recruited with the same verification rigour MedPanel applies to all formats — condition-confirmed, with disease stage and treatment status controlled to prevent within-group heterogeneity from obscuring meaningful signal. For more, see our rare disease survey research, rare disease focus groups, and rare disease research overview.
Emotional Sensitivity Protocols and IRB-Aligned Consent
Rare disease qualitative research involves populations that carry a level of vulnerability standard market research protocols are not designed to manage — patients with progressive, life-limiting, or paediatric-onset conditions; caregivers managing clinical complexity and emotional labour; and communities where stigma, isolation, and medical trauma are common. Therefore, all require design and moderation that goes beyond professional courtesy.
Accordingly, MedPanel’s rare disease qualitative protocols are built around three non-negotiable standards.
- IRB-aligned informed consent is applied to all qualitative research involving patients and caregivers. Specifically, consent documentation is prepared in plain language appropriate to the population, reviewed for comprehension accessibility, and administered with a mandatory reflection period before any engagement begins. Moreover, where research meets the threshold for human subjects research, MedPanel manages the full IRB review pathway across US, EU, UK, and APAC ethics bodies.
- Emotional sensitivity moderation means our rare disease moderators are trained specifically for high-vulnerability contexts, not rotated from a general qualitative team. For instance, this includes distress recognition and response during live sessions, pre-session psychological safety framing, mandatory debrief resources at session close, and moderator debriefs after emotionally intensive fieldwork. In addition, for paediatric research, additional safeguarding protocols apply as standard.
- Participant welfare over data extraction. Our moderators are trained to prioritise participant welfare at every point. Where a participant shows signs of distress, sessions are paused or closed. Indeed, no research objective justifies continuation at the cost of participant harm, and this standard is written into our protocols rather than left to in-session discretion.
For sponsors, these standards matter beyond ethical obligation. Notably, research conducted without appropriate consent frameworks and vulnerability protocols carries regulatory risk, reputational exposure, and — if used in submissions — potential evidentiary challenges. Therefore, MedPanel builds compliance in from protocol design, not as a post-fieldwork audit. For related capability, see our rare disease patient recruitment and caregiver studies.
Remote Moderation for Globally Dispersed Communities
The global geography of rare disease expertise and patient populations does not map to the operational model of in-person qualitative research. For example, a condition affecting twelve thousand patients across thirty countries cannot be researched through local fieldwork agencies with in-person recruitment. Therefore, remote moderation is not a pandemic-era compromise in rare disease — it is the structurally correct format.
Specifically, MedPanel’s remote qualitative research infrastructure is built for rare disease scale.
- Platform security and compliance. All remote sessions run on HIPAA-compliant video platforms with end-to-end encryption, participant authentication, and data residency controls appropriate to the participant’s jurisdiction. Moreover, recording consent is managed within the platform workflow, not as a separate administrative step.
- Asynchronous qualitative methods complement live IDIs and focus groups for populations with physical limitations, significant time zone spread, or intermittent connectivity. For instance, text-based bulletin boards, video diary submissions, and structured digital journals enable participation from patients who cannot sustain a 60- to 90-minute synchronous session.
- Multi-language moderation is available across major European, Asian, and Latin American languages, with rare disease–trained moderators rather than general interpreters. Importantly, language capability is matched to moderator rare disease expertise, not traded off against it.
- Global participant coordination. Our participant management team operates across time zones to schedule, brief, and support participants in every region. As a result, logistical friction does not become a source of attrition in already-small sample populations.
For more, see our rare disease patient recruitment and rare disease research overview.
From Raw Insight to Strategic Evidence
Rare disease qualitative research generates data that must be transformed into evidence — structured, interpretable, and actionable for medical affairs, HEOR, regulatory, and commercial audiences with different evidentiary requirements. Accordingly, MedPanel delivers qualitative outputs in four formats, each designed for a specific downstream use.
- Thematic analysis reports present findings as structured themes derived from systematic coding of transcript data, with frequency and salience indicators, anonymised illustrative quotes, and an interpretation layer that maps themes directly to the sponsor’s research questions. Specifically, they suit internal review, advisory board presentation, and publication preparation.
- Patient journey maps synthesise findings into a visual, longitudinal representation of the patient experience from first symptom through diagnosis, treatment initiation, and ongoing management. Notably, these are high-value outputs for medical education design, patient support programme architecture, and disease awareness strategy.
- Verbatim insight reports provide sponsor teams with the unmediated participant voice — curated, anonymised excerpts organised by theme and participant profile, with moderator context notes. For example, commercial and advocacy teams use this format for messaging development, campaign design, and HCP education materials.
- Publication-ready qualitative manuscripts are available for sponsors with peer-reviewed publication as an objective. Specifically, our analysis team produces manuscripts aligned to COREQ standards, with full methodology transparency. Indeed, our record of seven published, peer-reviewed studies reflects the scientific standard our qualitative research is designed to meet.
For related capability, see our rare disease survey research, caregiver studies, and HEOR and health economics research.
Book a consultation
Book a Rare Disease Qualitative Research Consultation
Whether you are designing a patient journey study, evaluating PRO instrument content, exploring treatment decision-making with specialist physicians, or building the qualitative foundation for an HTA submission, MedPanel’s rare disease research team will design a study that meets your scientific objectives and your population’s specific requirements.
The right qualitative format recommended
A recruitment approach outlined
IRB requirements confirmed for your geographies
A study built to your scientific objectives
Share your condition area, your research question, and your timeline. We will recommend the right qualitative format, outline a recruitment approach, and confirm IRB requirements for your target geographies.